Drugs.com Clinical Trial ResultsOriginal article
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
RegulatoryapprovedIKT-001Positive
AI Analysis
Summary
Inhibikase Therapeutics announced that its lead candidate IKT-001 received FDA Orphan Drug Designation for the treatment of Pulmonary Arterial Hypertension, a rare disease indication.
Outcome Details
FDA Orphan Drug Designation granted
Importance:6/10
Sentiment:
0.70
orphan drug designationFDAPAHIKT-001regulatory milestone
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on July 23, 2026 12:07 AM